In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.
The COVID-19 pandemic magnified the crucial role of primary care in advancing population health. Payers and providers are collaborating in novel ways to expand access to quality, affordable primary care.
In the latest Matters in Managed Care webinar from The American Journal of Managed Care® (AJMC)®, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed sat down to discuss how payers and primary care providers are managing patient needs during this time of pandemic change, including efforts to expand access to value-based care and connect behavioral/mental health, health equity, and primary care.
Brian Klausner, MD, medical director, Community Population Health at WakeMed Primary Care, moderated the June 2021 discussion with Devdutta Sangvai, MD, MBA, vice president, Population Health Management, Duke University Health System; Leslie McKinney, MD, FACEP, senior medical director, Blue Cross NC Advanced Primary Care and Value-Based Provider Engagement; and Rivers Woodward, MD, MBA, family physician, and Blue Ridge Community Health Services.
In part 3, the panel reviews population health opportunities and challenges.
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
New PsA Data Highlight Long-Term Benefits of Bimekizumab
November 19th 2024A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).
Read More